<!doctype html><html lang=en><head><meta charset=utf-8><meta name=HandheldFriendly content="True"><meta name=MobileOptimized content="320"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=referrer content="no-referrer"><meta name=description content="Asked how Novavax plans to market its vaccine in the United States, a company spokesperson said the need for additional vaccine options continues and that the biotech is engaged in educational efforts aimed at increasing understanding about our science."><meta name=robots content="index,follow,noarchive"><link href="https://fonts.googleapis.com/css?family=Open+Sans:400|Old+Standard+TT:400&display=swap" rel=stylesheet media=print type=text/css onload='this.media="all"'><title>Few Unvaccinated Adults Are Interested in Novavax's COVID-19 Shots</title><link rel=canonical href=./novavax-protein-based-covid-vaccine-survey.html><style>*{border:0;font:inherit;font-size:100%;vertical-align:baseline;margin:0;padding:0;color:#000;text-decoration-skip:ink}body{font-family:open sans,myriad pro,Myriad,sans-serif;font-size:17px;line-height:160%;color:#1d1313;max-width:700px;margin:auto}p{margin:20px 0}a img{border:none}img{margin:10px auto;max-width:100%;display:block}.left-justify{float:left}.right-justify{float:right}pre,code{font:12px Consolas,liberation mono,Menlo,Courier,monospace;background-color:#f7f7f7}code{font-size:12px;padding:4px}pre{margin-top:0;margin-bottom:16px;word-wrap:normal;padding:16px;overflow:auto;font-size:85%;line-height:1.45}pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}pre code{display:inline;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}pre code::before,pre code::after{content:normal}em,q,em,dfn{font-style:italic}.sans,html .gist .gist-file .gist-meta{font-family:open sans,myriad pro,Myriad,sans-serif}.mono,pre,code,tt,p code,li code{font-family:Menlo,Monaco,andale mono,lucida console,courier new,monospace}.heading,.serif,h1,h2,h3{font-family:old standard tt,serif}strong{font-weight:600}q:before{content:"\201C"}q:after{content:"\201D"}del,s{text-decoration:line-through}blockquote{font-family:old standard tt,serif;text-align:center;padding:50px}blockquote p{display:inline-block;font-style:italic}blockquote:before,blockquote:after{font-family:old standard tt,serif;content:'\201C';font-size:35px;color:#403c3b}blockquote:after{content:'\201D'}hr{width:40%;height:1px;background:#403c3b;margin:25px auto}h1{font-size:35px}h2{font-size:28px}h3{font-size:22px;margin-top:18px}h1 a,h2 a,h3 a{text-decoration:none}h1,h2{margin-top:28px}#sub-header,.date{color:#403c3b;font-size:13px}#sub-header{margin:0 4px}#nav h1 a{font-size:35px;color:#1d1313;line-height:120%}.posts_listing a,#nav a{text-decoration:none}li{margin-left:20px}ul li{margin-left:5px}ul li{list-style-type:none}ul li:before{content:"\00BB \0020"}#nav ul li:before,.posts_listing li:before{content:'';margin-right:0}#content{text-align:left;width:100%;font-size:15px;padding:60px 0 80px}#content h1,#content h2{margin-bottom:5px}#content h2{font-size:25px}#content .entry-content{margin-top:15px}#content .date{margin-left:3px}#content h1{font-size:30px}.highlight{margin:10px 0}.posts_listing{margin:0 0 50px}.posts_listing li{margin:0 0 25px 15px}.posts_listing li a:hover,#nav a:hover{text-decoration:underline}#nav{text-align:center;position:static;margin-top:60px}#nav ul{display:table;margin:8px auto 0}#nav li{list-style-type:none;display:table-cell;font-size:15px;padding:0 20px}#links{display:flex;justify-content:space-between;margin:50px 0 0}#links :nth-child(1){margin-right:.5em}#links :nth-child(2){margin-left:.5em}#not-found{text-align:center}#not-found a{font-family:old standard tt,serif;font-size:200px;text-decoration:none;display:inline-block;padding-top:225px}@media(max-width:750px){body{padding-left:20px;padding-right:20px}#nav h1 a{font-size:28px}#nav li{font-size:13px;padding:0 15px}#content{margin-top:0;padding-top:50px;font-size:14px}#content h1{font-size:25px}#content h2{font-size:22px}.posts_listing li div{font-size:12px}}@media(max-width:400px){body{padding-left:20px;padding-right:20px}#nav h1 a{font-size:22px}#nav li{font-size:12px;padding:0 10px}#content{margin-top:0;padding-top:20px;font-size:12px}#content h1{font-size:20px}#content h2{font-size:18px}.posts_listing li div{font-size:12px}}@media(prefers-color-scheme:dark){*,#nav h1 a{color:#fdfdfd}body{background:#121212}pre,code{background-color:#262626}#sub-header,.date{color:#bababa}hr{background:#ebebeb}}</style></head><body><section id=nav><h1><a href=./index.html>JadeSync</a></h1><ul><li><a href=./index.xml>Rss</a></li><li><a href=./sitemap.xml>Sitemap</a></li></ul></section><section id=content><h1>Few Unvaccinated Adults Are Interested in Novavax's COVID-19 Shots</h1><div id=sub-header>May 2024 · 3 minute read</div><div class=entry-content><img src=https://cdn.statically.io/img/pro-assets.morningconsult.com/wp-uploads/2022/07/29153129/Novavax-COVID-19-Vaccine-GettyImages-1231129067-scaled.jpg style=margin:auto;display:block;text-align:center;max-width:100%;height:auto><p class="mb-m last:mb-0 text-body-large">Asked how Novavax plans to market its vaccine in the United States, a company spokesperson said the “need for additional vaccine options continues” and that the biotech is “engaged in educational efforts aimed at increasing understanding about our science.”</p><h2 class="font-semibold text-headline2 leading-headline2 mb-m"><strong>Novavax could find U.S. opening via booster shot campaign</strong></h2><p class="mb-m last:mb-0 text-body-large">Meanwhile, the Novavax vaccine could be an appealing booster dose for those who have already gotten vaccinated, Hotez said, but only if the biotech can prove that the shot offers strong levels of protection following mRNA vaccination. Last week, <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>Novavax said</a> final clinical trial data is expected in September and that the company is “prepared to supply an Omicron-based vaccine this fall” as part of the U.S. booster campaign.</p><p class="mb-m last:mb-0 text-body-large">The fall booster effort may prove challenging, given the ongoing campaign has lagged. Federal data shows that <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>fewer than half</a> of vaccinated adults have gotten a first booster dose.</p><p class="mb-m last:mb-0 text-body-large">“There was a terrible mistake made by the Centers for Disease Control and Prevention, in calling people with two doses fully vaccinated,” said Hotez, whose lab <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>developed a COVID-19 vaccine</a> that is available in India. “That was never really the case, but they still clung to that outdated concept.”</p><p class="mb-m last:mb-0 text-body-large">Dr. Leana Wen, an emergency physician and professor at George Washington University, said the most eager cohort for Novavax’s shots will likely be those who have kept up to date on their COVID-19 vaccinations.</p><p class="mb-m last:mb-0 text-body-large">“I don’t even think that we will need to spread the message,” Wen said. “There is a group of people who are so eager to get the best protection possible, they are awaiting any news of anything that they can be taking.”</p><p class="mb-m last:mb-0 text-body-large">The FDA is <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>reviewing changes</a> to Novavax’s manufacturing process before it authorizes the shot, but even if it gains clearance, it may be some time before the vaccine is widely available. While the company has pledged <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>110 million doses</a> to the United States and another 1.1 billion for low-income countries, it’s struggled to ramp up production. Novavax’s spokesperson said the company is “working with the U.S. government to finalize our order” and has “millions of doses ready to ship.”</p><p class="mb-m last:mb-0 text-body-large">Ultimately, Hotez said Novavax is under pressure to deliver, given it received <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>$1.6 billion in federal funding</a> through the Trump administration’s Operation Warp Speed vaccine development program. <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>He has said</a> his own team got $400,000 from the U.S. government to develop its shot.</p><p class="mb-m last:mb-0 text-body-large">“If it were offered to me, I would take it in a heartbeat,” Hotez said of the Novavax vaccine’s promise as a COVID-19 booster. “Right now, the American people are balking at getting an mRNA booster every few months.”</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmiooqR7rrvRp6Cnn5Oku7TBy61lnKedZMGzsc2dZKydpKmys7%2BOp6avmaaWxW680airnqGeYq%2Biv8SdZJynpp6xbsLAnJqippViwLa%2B1Z6w</p></div><div id=links><a href=./how-much-money-does-mili-avital-make-html.html>&#171;&nbsp;How Much Money Does Mili Avital Make? Latest Income Salary</a>
<a href=./ekiti-state-news-today.html>Ekiti State News Today | Daily Updates&nbsp;&#187;</a></div></section><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/banner.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>